Molecular Detection of blaTEM, blaCTX-M and blaSHV Genes in Extended Spectrum β -Lactamase (ESBL) Escherichia Coli from Clinical Samples

Mahesh Kumar Chaudhary (✉ maresh_3272@yahoo.com)

Mediciti Hospitals <https://orcid.org/0000-0002-9713-961X>

Indrani Jadhav

Jaipuria Institute of Management Jaipur

Megha Raj Banjara

Tribhuvan University

Research

Keywords: E.coli, Extended spectrum β -lactamase, Multidrug resistant

Posted Date: October 29th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-965153/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Extended spectrum β -lactamases are the group of beta-lactamase enzymes which confer resistance to the oxyimino-cephalosporins and monobactams. Emergence of ESBL producing genes which possess a serious threat for the treatment of infections both in community and hospitals since it is found to be increasing trends of multidrug resistance. This study was focused to find out the ESBLs producing genes.

Methods

This was a cross-sectional study conducted over a period of 2 years (September 2018 to April 2020) at microbiology laboratory of Nepal Medcity Hospital. Clinical samples were processed in microbiology laboratory and culture isolates were identified and characterized by standard microbiological techniques following standard procedures. Antibiotic susceptibility testing was performed by modified Kirby-Bauer disc diffusion method as recommended by Clinical and Laboratory Standard Institute. Extended spectrum beta-lactamases were phenotypically confirmed by combined disc method. ESBL producing genes i.e. blaTEM, blaCTX-M and blaSHV were confirmed by PCR.

Results

Of the 1449 total *E.coli* isolates, 323/1449(22.29%) isolates were multi-drug resistance. Among total MDR *Escherichia coli* isolates, 215/323(66.56%) isolates were ESBL producers. The maximum number of ESBL *Escherichia coli* was isolated from urine 194(90.23%), followed by sputum 12(5.58%), swab 5 (2.32%), pus 2 (0.93%) and blood 2 (0.93%). Antibiotic susceptibility pattern of ESBL *E.coli* producers showed highest sensitivity towards tigecycline (100%) followed by polymyxin b, colistin and meropenem. Out of 215 phenotypically confirmed ESBL *E.coli*, only 186(86.51%) isolates were found to positive by PCR. The last 29(13.49%) were negative for any of the resistant genes. Among the ESBL genotypes, most common was blaTEM 118(63.4%) followed by blaCTX-M 68(36.6%).

Conclusion

The emergence of MDR and ESBL producing *E.coli* isolates with high antibiotic resistant rates to commonly used antibiotics and increased predominance of major gene types blaTEM is a serious concern to the clinicians as well as microbiologist. This study forwarded a real message to all the clinicians for the emergence of XDR and PDR resistant bacteria and preservation of antibiotics for their proper use in near future, if past experience with MDR and ESBLs is any indicator.

1. Introduction

Extended-spectrum beta-lactamases (ESBLs) are the group of beta-lactamase enzymes, which hydrolyze and cause resistance to the oxyimino-cephalosporins (cefotaxime, ceftazidime, ceftriaxone, cefuroxime and cefepime) and monobactams (aztreonam), but not

the cephamycins (cefoxitin and cefotetan) or carbapenems (imipenem, meropenem, and ertapenem), produced by *Escherichia coli* and *Klebsiella pneumoniae*.¹

Emergence of resistant bacteria worldwide as a threat to favorable outcomes of treatment of common infections in community and hospital settings. *E.coli* is one of the commonest pathogen to exhibit multidrug resistance. Important risk factors for infection with MDR and ESBL *Escherichia coli* are prolonged antibiotic exposure, overstay in hospital, increased use of third generation cephalosporins, severe illness, increased use of intravenous devices or catheters.²

The first ESBL was identified from Germany in 1983, from France in 1985, from United States at end of 1980s, and the beginning of the 1990s.³ New TEM and the SHV enzymes are still emerging in Europe, and distinct epidemic clones have been found, for example *E. coli* and *K. pneumoniae* isolates with SHV-12 in Italy.⁴ Isolates with the CTX-M-9 group are common in Spain and strains with the CTX-M-3 enzymes have been described chiefly in Eastern Europe, although clones producing the CTX-M group 1 (including the CTX-M-15 type) are the most widespread throughout Europe.^{5,6,7}

The rapid increase in extended spectrum beta lactamases with the existence of multidrug resistant organisms is a global problem. The prevalence of ESBL producing organisms is more than 20% in Asia and South Africa. The detection of major genes such as *bla*TEM, *bla*CTX-M and *bla*SHV in ESBL producing *E.coli* by molecular methods and their antibiotic resistance pattern can provide valuable information about their epidemiology and help in formulation of rational antimicrobial therapy.⁸

In Developing country like Nepal also due to the increasing incidence of ESBL producing *Escherichia coli*, the cost associated with the consequences also rises, so considered as an economic burden on the patients both in community and in hospital set up. Therefore, this study was conducted with the objectives of studying the spectrum of MDR and ESBL *Escherichia coli* producing strains and molecular characterization of these resistant genes. Characterization of ESBL *Escherichia coli* at molecular level may be beneficial to analyze the root cause of ESBL pattern which may help to make a positive contribution to current understanding and knowledge of the situation caused by ESBL *Escherichia coli* producing strains and for the development of better treatment strategy and prevention of the disease.

2. Material And Methods

2.1 Sample processing and Identification of Organisms

A cross sectional study was conducted in Microbiology Laboratory of Nepal Medcity Hospital, Bhaishepati; Nepal from September 2018 to April 2020. The ethical approval was taken from the Ethical Review Board of Nepal Health Research Council (NHRC), Kathmandu, Nepal. A total of 16542 clinical samples sent to the microbiology laboratory were processed and cultured by standard microbiological techniques. The identification of bacterial isolates were carried out by cultural, morphological characters, Gram stain

and appropriate biochemical tests (triple sugar iron, indole, citrate, urease and motility) following standard procedures.

2.2 Antibiotic Susceptibility Tests

Antibiotic susceptibility testing was performed by modified Kirby-Bauer disc diffusion method as recommended by Clinical and Laboratory Standard Institute. The antibiotics used were amikacin (30µg), gentamycin (10µg), ciprofloxacin (30µg), ceftriaxone (30µg), cefotaxime (30µg), ceftazidime (30µg), nitrofurantoin (300µg), norfloxacin (10µg), nalidixic acid (30µg), ofloxacin (5µg), cotrimoxazole (25µg), cefixime (5µg), cefepime (30µg), tigecycline (15µg), imipenem (10µg), meropenem (10µg), polymyxin B (300µg) and colistin (10µg). Plates were incubated aerobically at 37°C for 24 hours. Zone diameter in millimeters was measured and organisms were identified as sensitive, resistant and intermediate as per CLSI 2013 guidelines. *Escherichia coli* strain ATCC 25922 was used as control strain.

2.3 Screening of ESBL

The screening was done by disc diffusion technique using 3rd generation cephalosporins (ceftazidime, cefotaxime and ceftriaxone). Isolates resistant to more than one of these agents were identified as possible ESBL producers.^{9, 10}

2.4 Confirmation of ESBL

For confirmation, combined disc test was performed using Ceftazidime (30µg) alone and ceftazidime with clavulanic acid (30µg/10µg) and cefotaxime (30µg) and cefotaxime with clavulanic acid (30µg/10µg). A difference in zone of inhibition by ≥ 5 mm of either of ceftazidime clavulanic acid with ceftazidime alone and cefotaxime clavulanic acid with cefotaxime alone was interpreted as confirmed ESBL.¹¹

2.5 Gene Identification

From confirmed ESBL *E. coli*, plasmid DNA was extracted using alkaline hydrolysis method. These plasmid DNA served as a template for PCR amplification using bla_{TEM}, bla_{CTX-M} and bla_{SHV} specific primers (Marecogen, Korea). For PCR amplification, 1.5µl plasmid DNA was added to 25 µl mixture containing 13 µl master mixture (Solis Biodyne, Estonia), 10.5µl nuclease free water and 0.5µl each of reverse and forward primers. PCR was performed in 5 Prime/02 thermal cycler using optimized condition. Bibby Scientific, U.K. using optimized condition. For bla_{TEM} gene identification, initial denaturation at 94°C for 5 minutes followed by 30 cycles of each of denaturation (95°C for 45 seconds), annealing at (50°C for 45 seconds), and extension at (72°C for 30 seconds), and final extension at (72°C for 10 minutes). For bla_{SHV} and bla_{CTX-M} genes, initial denaturation at 94°C for 5 minutes followed by 30 cycles of each of denaturation (95°C for 45 seconds), annealing at 56°C for 45 seconds and 62°C for 45 seconds respectively, and extension at (72°C for 30 seconds), and final extension at (72°C for 10 minutes). The amplified product was subjected to gel electrophoresis (2% gel stained with ethidium

bromide) at 70v for 45 minutes. DNA ladder (100bp) was used to estimate the molecular weight of amplified products. After electrophoresis, gel doc system was used for photo documentation.

2.6 Control

For ESBL test, *Escherichia coli* (ATCC 25922), *Klebsiella pneumoniae* (ATCC 700603) were taken as negative control and positive control respectively. Confirmed *Escherichia coli* strains harbouring *bla*TEM, *bla*SHV, *bla*CTX-M were taken as positive control and nuclease free water as negative control.

2.7 Statistical Analysis

Data were entered and percentage calculation were analyzed by using Statistical Package for Social Science (SPSS) version 21.

3. Results

1449 *Escherichia coli* isolates were recovered from various clinical samples. The highest number of *Escherichia coli* was isolated from urine followed by sputum, swab, pus, blood, fluid, foley's tip, vaginal swab, catheter tip, BAL, biopsy, bile suction tube, CVP tip, ET tube. Of the 1449 total *E. coli* isolates, 323/1449 (22.29%) isolates were multi-drug resistance. Among total MDR *Escherichia coli* isolates, 215/323 (66.56%) isolates were ESBL producers. The maximum number of ESBL *Escherichia coli* was isolated from urine 194 (90.23%), followed by sputum 12 (5.58%), swab 5 (2.32%), pus 2 (0.93%) and blood 2 (0.93%).

Specimen	ESBL <i>E. coli</i> No (%)
Urine	194(90.23%)
Sputum	12(5.58%)
Swab	5(2.32%)
Pus	2(0.93%)
Blood	2(0.93%)
Total	215(100.0)

Antibiotic susceptibility pattern of ESBL *E. coli* producers showed highest sensitivity towards tigecycline (100%) followed by polymyxin b, colistin and meropenem.

Antibiotics	Antibiotic susceptibility rate No (%) ESBL <i>E.coli</i> (215)	
	Sensitive	Resistant
Amikacin(AK)	197(91.6)	18(8.4)
Gentamycin(G)	180(83.7)	35(16.3)
Ciprofloxacin(CIP)	125(58.2)	90(41.8)
Ceftriaxone(CTR)	-	215(100)
Cefotaxime(CTX)	1	214(97.3)
Ceftazidime(CAZ)	-	215(100)
Nitrofurantion(NIT)*	182(93.8)	12(6.2)
Norfloxacin(NX)*	109(56.2)	85(43.8)
Nalidixic acid(NA)*	9(4.6)	185(95.4)
Ofloxacin(OF)*	91(46.9)	103(53.1)
Tigecycline(TGC)	215(100)	-
Imipenem(IPM)	148(68.8)	67(31.2)
Meropenem(MRP)	194(90.2)	21(9.8)
Polymyxin B(PB)	215(100)	-
Colistin(CL)	215(100)	-

Two hundred fifteen ESBL *E.coli* isolates were confirmed by PCR using *bla*TEM, *bla*CTX-M and *bla*SHV specific primers. Out of 215 phenotypically confirmed ESBL *E.coli*, only 186(86.51%) isolates were found to be positive by PCR. The last 29(13.49%) were negative for any of the resistant genes. Among the ESBL genotypes, the most common was *bla*TEM 118(63.4%) followed by *bla*CTX-M 68(36.6%). (Figure 3. Figure 4). The co-existence of *bla*TEM and *bla*CTX-M in ESBL producing *E.coli* was 39(20.96%). No ESBL *E.coli* isolates co-harbored *bla*SHV and *bla*TEM, *bla*CTX-M and *bla*SHV or all three genes at the same time.

ESBL genotypes	ESBL producing <i>E.coli</i> (n=186) No (%)
<i>bla</i> TEM	118(63.4%)
<i>bla</i> CTX-M	68(36.6%)
<i>bla</i> TEM + <i>bla</i> CTX-M	39(20.96%)
<i>bla</i> SHV	0(0)

Discussion

Despite the discovery of antibiotics, emergence of MDR and ESBLs producing bacteria due to the extensive use of extended spectrum cephalosporins (ESCs) since early 1980's is a significant evolution in antimicrobial resistance. Several other factors including misuse of drugs, inappropriate antibiotic treatment, extensive use of antimicrobials has also contributed to the emergence of drug resistant bacteria. The present study was conducted in the department of microbiology laboratory, Nepal Medicity Hospital during a period of September 2017 to April 2019 with the aim of understanding the antibiotic profile of MDR and ESBL producing *Escherichia coli*.

The present study documented that the highest number of *E.coli* isolates were recovered from urine (n=1098(75.77)). With regard to urinary tract infection, *E.coli* showed great extent of resistance to nalidixic acid, co-trimoxazole and third generation cephalosporins. Similar pattern of resistant in urinary isolates of *E.coli* was shown in Nepal and India.^{12, 13, 14} In contrast to our result, Perez et.al reported *E.coli* isolates were 94% resistant to ceftriaxone¹⁵ This may be due to the irrational use of third generation cephalosporins.¹⁶ However; a significant degree of susceptibility was found to nitrofurantoin (96.5%) followed by amikacin (80.7%) and gentamycin (73.9%). Similar findings have been reported in various studies.^{12, 13, 14, 17, 11, 18} This may be due to the rational use of these drugs in UTIs cases since it is reserved drug for UTIs.

In this study, analysis of antibiotic susceptibility of *E.coli* isolated from sputum, blood, swab, pus demonstrated a significant degree of susceptibility towards tigecycline (100%) followed by colistin (98% to 100%), polymyxinb (97% to 100%), meropenem (91% to 96%) and imipenem (79% to 90%). Similar results were shown in other studies.^{14, 19} It was found to be higher resistant pattern of cephalosporins(22% to 93%), fluoroquinolones(26% to 85%), aminoglycosides(8% to 59%) as compared to urine isolates. Several studies conducted in Nepal showed similar results.^{12, 19, 20} In contrast to our study, Bamford et al. noted higher susceptibility pattern towards cephalosporins, fluoroquinolones, aminoglycosides.²¹ The increased level of drug resistance is a major concern worldwide since these are the first line drugs recommended internationally.^{22, 23} and are irrational used in public and private sectors.^{24, 25.}

The present study noted (323/1449)22.29% MDR *E.coli* isolates that were suspected of being ESBL producers were confirmed by combined disc method. Prevalence of ESBL *E.coli* was (215/323)66.56% which was alarming high. Several studies reported high prevalence i.e.40-70% of ESBL *E.coli* among MDR *E.coli*.^{11, 26, 27, 28, 29, 19} Kashyap et.al reported 37% ESBL *E.coli*.³⁰ But the study conducted by Anil chander et.al in 2013 observed only 13.51% ESBL prevalence in *E.coli* which is analogous result to other study.^{31, 32.} This is not similar with our study due to the variation in geography, study design and selection of type of antimicrobial agents. The indiscriminate use of beta-lactam antibiotics leads to the generation of selective pressures which have led to the selection of a variety of mutated forms of beta lactamases.^{33.} Antibiotic profile of ESBL producing *E.coli* were found to be higher sensitivity towardstigecycline(100%), polymyxin B (100%), colistin(100%) followed by amikacin(91.6%), meropenem(90.2%)and imipenem(68.8%). Susceptibility to nitrofurantoin was 93.8%

against ESBL producing *E.coli* isolated from urine. So, it is the drug of choice for treating infection caused by ESBL producing *E.coli*. The result of similar study conducted in Nepal and India.^{34, 14, 8} High resistant rates were observed to cephalosporins, nalidixic acid followed by fluoroquinolones. Similar findings were reported by Al-Zarouni et. Al.³⁵

In the present study, out of 323 MDR *E.coli* isolates, ESBL *E.coli* phenotypes were found to be positive in 215(66.56%) isolates. Similar findings were reported by Dalela et.al, 2012, Ozcakar et.al, 2011.^{36,37} The frequency of phenotypic ESBL positive *E.coli* 29 (13.49%) isolates were lacked blaTEM, blaCTX-M and blaSHV genes. Which could be false positive results by phenotypic methods or can be possible presence of other ESBL encoding genes such as SFO, BES, BEL, TLA, GES, PER and VEB types and structural changes in penicillin-binding proteins that result in resistance to β -lactam antibiotics.^{36.38.39.40}

In this study, the overall prevalence of ESBL genes was 186 (86.51%). Which is similar to other findings reported by Marthie et.al, 2009 in South Africa, Ruben et.al, 2014 in Portugal.^{39,41} PCR analysis revealed the presence of blaTEM, blaCTX-M and blaSHV genes in ESBL producing *E.coli* was 118(63.4%), 68(36.6%) and 0(0) respectively. In the present study, blaTEM was the most predominant genotype of ESBL among *E.coli* isolates. This study is well supported by Ruben et.al, 2014 in Portugal, Noha et.al, 2020 in Upper Egypt, Majid et.al, 2017 in Iran, Pandit et.al, 2020 in Nepal, Bali et.al, 2010 in Turkish. Michael et.al, 2018 in Iraq, Jena et.al, 2017 in India, Seyedjavadi et.al, 2016.^{41.42,40,43,44,45,46,47}

However, several literatures reported the prevalence of blaTEM type ESBL producing *E.coli* was less than this study. In Nepal, some study done by Pokhrel et.al, 2014, Lohani et.al, 2019 reported 29.2%, 34.6% blaTEM type ESBL *E.coli* respectively.^{48.49}

In recent years, non-TEM and non-SHV plasmid mediated ESBLs mainly the CTX-M gene, a predominant type of ESBL found in many regions of the world, including Asia, South America, Europe and Africa have been reported and it has been explained under the term "CTX-M β -lactamase pandemic".^{50,51,52}

In the present study, the prevalence of blaCTX-M genes were found to be 68 (36.6%) which concurs with various reports demonstrating the extensive worldwide dissemination of blaCTX-M genes in ESBL producing *E.coli* isolates.⁵³ However, another study from Nepal has reported the high prevalence of blaCTX-M genes (95.2%) by Pokhrel et.al 2014 and (100%) by Lohani et.al 2019 and (91.4%) by Parajuli et.al, 2016.^{48,49,54} Similarly, George et.al, 2015 reported high prevalence of CTX-M type *E.coli* (91.8%) in India.⁵⁵ Moreover, the lower prevalence of CTX-M gene among ESBL producing *E.coli* does not co-relate with study done by Moses et.al. and Sharma et.al.^{56,57} Kiratisin et.al. reported blaCTX-M (99.6%) of ESBL producing *E.coli* from Thailand.⁵⁸

The differences in frequencies of the prevalence of these genes may be as a result of differences in time by which isolates were collected and differences in volume and type of antibiotic consumption.⁵⁹

Furthermore, multiple harboring of genes in a single ESBL producing *E.coli* was also noted. The most common combination gene was blaTEM + blaCTX-M type 39 (20.96%). Our finding is in agreement with the study by Lohani et.al where (21.2%) of blaTEM and blaCTX-M genes were reported.⁴⁹ Similar report was shown by Majid et.al.2017.⁴⁰ Whereas genotypic combination of blaSHV + blaCTX-M, blaSHV + blaTEM and blaSHV + blaCTX-M + blaTEM were not detected.

The presence of multiple genotypes in a single isolate might be the result of complex antibiotic resistance pattern.⁶⁰ Our findings does not agree with the study of Kaftandzieva et al, 2012 and Ibrahim et.al, 2015 where they reported blaTEM and bla SHV type (16%) and (2.27%) respectively.^{61, 62} Similarly, El bouamri et.al,2015 reported CTX-M +TEM and CTX-M +SHV type (6%) and (12%) respectively.⁶³

Regarding the blaSHV gene, no blaSHV type *E.coli* was detected in our study. Which is similar to the study in China.⁶⁴ However, several findings in Nepal reported the prevalence of blaSHV gene.^{48,49,54} But the prevalence of blaSHV gene reported by Varkey et.al,2014 in India was quite high (66%).⁶⁵

Conclusion

In conclusion, the present study highlights the emergence of MDR and ESBL producing *E.coli* isolates with high antibiotic resistant rates to commonly used antibiotics and increased predominance of major gene types blaTEM is a serious concern to the clinicians as well as microbiologist. Since the spread of MDR and ESBL producing *E.coli* has been increasing rapidly worldwide including developing country like Nepal, treatment options for resistant bacteria have been increasingly sorted. In the present study, no resistance was documented to tigecycline, polymyxin b, and colistin suggesting the suitable drug of choice for treating ESBL producing *E.coli* causing life threatening infections. Therefore, molecular detection and identification of ESBL producing bacterial isolates should be essential at routine laboratory level. Of particular concern, our findings emphasizes the need for implementation of strict antibiotic policy, clinical care management and antibiotic stewardship program absolutely required in each and every health sectors by all concern authorities. This study forwarded a real message to all the clinicians for the emergence of XDR and PDR resistant bacteria and preservation of antibiotics for their proper use in near future, if past experience with MDR and ESBLs is any indicator.

Declarations

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENT

We would like to acknowledge Nepal Medcity Hospital, Nepal for providing ethical approval and research work. We also thank to the microbiology laboratory staffs for their valuable support to complete this

work.

References

1. Lal P, Kapil A, Das BK and Sood S. Occurrence of TEM and SHV gene in extended spectrum beta lactamases (ESBLs) producing *Klebsiella spp.* isolated from a tertiary care hospital. *Indian Journal Medica.*2007; 125: 173-178.
2. Chaudhary U, Aggarwal R. Extended spectrum β -lactamases (ESBL): Emerging threat to clinical therapeutics. *Indian J Med Microbiol.*2004; 22(2):7 [https://doi.org/10.1016/S0255-0857\(21\)02884-X](https://doi.org/10.1016/S0255-0857(21)02884-X)
3. Rice, L.B., Willey, S.H., Papanicolaou, G.A., Medeiros, A.A., Eliopoulos, G.M., Moellering, R.C.J., Jacoby, G.A.. Outbreak of ceftazidime resistance caused by extended-spectrum betalactamases at a Massachusetts chronic-care facility. *Antimicrob. Agents Chemother.* 1990; 34 (11), 2193–2199. <https://doi.org/10.1128/AAC.34.11.2193>
4. Perilli, M., Segatore, B., Mugnaioli, C., Celenza, G., Rossolini, G.M., Stefani, S., Luzzaro, F., Pini, B., Amicosante, G. Persistence of TEM-52/TEM-92 and SHV-12 Extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Italy. *Microb. Drug Resist.*2011; 17 (4), 521–524. DOI: [10.1089/mdr.2011.0059](https://doi.org/10.1089/mdr.2011.0059)
5. Canton, R., Novais, A., Valverde, A., Machado, E., Peixe, L., Baquero, F., Coque, T.M. Prevalence and spread of extended-spectrum beta-lactamase producing Enterobacteriaceae in Europe. *Clin. Microbiol. Infect.*2008; 1:144–153. DOI: [10.1111/j.1469-0691.2007.01850.x](https://doi.org/10.1111/j.1469-0691.2007.01850.x)
6. Coque, T.M., Baquero, F., Canton, R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. *Euro. Surveill.*2008a; 13 (47), 1–11. DOI:[10.2807/ese.13.47.19044-en](https://doi.org/10.2807/ese.13.47.19044-en)
7. Coque, T.M., Novais, A., Carattoli, A., Poirel, L., Pitout, J., Peixe, L., Baquero, F., Canton, R., Nordmann, P. Dissemination of clonally related *Escherichia coli* strains expressing extended spectrum beta-lactamase CTX-M-15. *Emerg. Infect. Dis.*2008b; 14 (2), 195–200. doi: [10.3201/eid1402.070350](https://doi.org/10.3201/eid1402.070350)
8. Kaur, M. and Aggarwal, A. (2013) Occurrence of the CTX-M, SHV and the TEM Genes among the Extended Spectrum Beta-Lactamase Producing Isolates of Enterobacteriaceae in a Tertiary Care Hospital of North India. *Journal of Clinical and Diagnostic Research*, 7, 642-645. <https://doi.org/10.7860/JCDR/2013/5081.2872>
9. Coudron PE, Moland ES, Sanders CC. Occurrence and detection of extended spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. *J. Clin Microbial.*1997; 35(10):2593-97. <https://doi.org/10.1128/JCM.35.10.2593-2597.1997>
10. Babypadmini S, Appalaraju B. Extended spectrum beta-lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae*-Prevalence and susceptibility pattern in a tertiary care hospital. *Indian J*

*Med Microbiol.*2004; 22(3):172-174 [https://doi.org/10.1016/S0255-0857\(21\)02830-9](https://doi.org/10.1016/S0255-0857(21)02830-9)

11. Thakur S, Pokhrel N, Sharma M. Prevalence of multidrug resistant enterobacteriaceae and extended spectrum beta-lactamase producing *E.coli* in urinary tract infection. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*.2013; 4:1615-1621.
12. Subedi S, Chaudhary M, Shrestha B. High MDR AND ESBL Producing *Escherichia coli* and *Klebsiella pneumoniae* from Urine, Pus and Sputum Samples. *British Journal of Medicine & Medical Research*.2016; 13(10):1-10. <http://dx.doi.org/10.9734/BJMMR/2016/23350>
13. Rimal U, Thapa S, Maharjan R. Prevalence of Extended Spectrum Beta-Lactamase Producing *Escherichia coli* and *Klebsiella species* from Urinary Specimens of Children attending Friendship International Children's Hospital. *Nepal Journal of Biotechnology*.2017; 5(1):32-38. <http://dx.doi.org/10.3126/njb.v5i1.18868>
14. Kumar D, Singh AK, Ali R, Chander Y. Antimicrobial Susceptibility Profile of Extended Spectrum β -Lactamase (ESBL) Producing *Escherichia coli* from Various Clinical Samples. *Infect Dis*.2014; 7:1-8. <https://doi.org/10.4137/idrt.s13820> <https://doi.org/10.4137/idrt.s13820>
15. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. *Curr Opin Pharmacol*.2007; 7:459-469. <https://doi.org/10.1016/j.coph.2007.08.003>
16. Shobha KL, Gowrish RS, Sugandhi R, Sreeja CK. Prevalence of extended spectrum beta lactamases in urinary isolates of *Escherichia*, *Klebsiella* and *Citrobacter species* and their antimicrobial susceptibility pattern in tertiary care hospital. *Ind J Pract Doct*.2007;3:1-2.
17. Chander A, Shrestha C. Prevalence of extended spectrum beta lactamase producing *Escherichai coli* and *Klebsiella pneumoniae* urinary isolates in a tertiary care hospital in Kathmandu, Nepal. *BMC Research Notes*.2013; 6:487. <https://doi.org/10.1186/1756-0500-6-487>
18. Chaudhari KB, Singh KG, Parajuli PK, Shrestha K. Incidence and susceptibility of uropathogens isolated among the patients at tertiary care hospital in Eastern Nepal. *J Nobel Med Coll*.2016;5:51-55. <https://doi.org/10.3126/jonmc.v5i2.16318>
19. Shrestha B, Shrestha S, Mishra SK, Kattel HPT, Tada T, Ohara H, et al. Phenotypic Characterization of Multidrug-resistant *Escherichia coli* with Special Reference to Extended-spectrum-beta-lactamases and Metallo-beta-lactamases in a Tertiary Care Center. *J Nepal Med Assoc*.2015;53(198):89-95. <https://doi.org/10.31729/jnma.2768>
20. Yadav K, Prakash S. Screening of ESBL Producing Multidrug Resistant *E.coli* from Urinary Tract Infection Suspected Cases in Southern Terai of Nepal. *J Infect Dis Diagn*.2017;2:2 <http://dx.doi.org/10.4172/2576-389X.1000116>

21. Bamford C, Bonorchis K, Ryan A, Hoffmann R, Naicker P, Maloba M, et al. Antimicrobial susceptibility patterns of *Escherichia coli* strains isolated from urine samples in South Africa from 2007-2011. *South Afr J Epidemiol Infect*. 2012;27(2):46-52. <http://dx.doi.org/10.1080/10158782.2012.11441483>
22. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011;52:e103-e120. <https://doi.org/10.1093/cid/ciq257>
23. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. *JAMA*. 2005;293:949-955. <https://doi.org/10.1001/jama.293.8.949>
24. Bosch F, van Vuuren C, Joubert G. Antimicrobial resistance patterns in outpatient urinary tract infections: the constant need to revise prescribing habits. *S Afr Med J*. 2011;101(5):328-331. <https://doi.org/10.7196/samj.4346>
25. Gumede L, Van der Hoven L, Maseko V, De Kock E, Smuts F, Perovic O, et al. Antimicrobial susceptibility profiles for community-acquired urinary tract pathogens in Gauteng province. Durban: *Southern African Journal of Epidemiology and Infection*. 2011;26(3):122-154. <https://doi.org/10.1080/10158782.2011.11441438>
26. Kulkarni DM, Bardapurkar SA, Nilekar SL, More SR. Prevalence of extended spectrum β -lactamase (ESBL) producing *E. coli* and *Klebsiella species* in urinary isolates. *IOSR J Dent Med Sci*. 2016;15:26-29. DOI: 10.9790/0853-1506052629
27. Sharma S, Bhat GK. Virulence factors and drug resistance in *Escherichia coli* isolated from extraintestinal infection. *Ind J Med Microbiol*. 2007; 25:369-373. <https://doi.org/10.4103/0255-0857.37341>
28. Goyal A, Prasad KN, Prasad A, Gupta S, Ghosal U, Ayyagari A. Extended-spectrum β -lactamases in *Escherichia coli* and *Klebsiella pneumoniae* and associated risk factors. *Indian J Med Res*. 2009;129:695-700. PMID: 19692752.
29. Rajan S, Prabavathy V. Antibiotic sensitivity and phenotypic detection of ESBL producing *E. coli* strains causing UTI in a community hospital Chennai, Tamil Nadu, India. *Webmed Central Pharm Sci*. 2012;3:1-17. http://www.webmedcentral.com/article_view/3840
30. Kashyap G, Gupta S, Mamoria PV, Durlabhji P, Jain D. Increasing prevalence of extended spectrum beta lactamases (ESBLs) producing *E. coli* and *Klebsiella spp* in outpatient departments (OPDs) patients in urinary tract infections (UTIs) in tertiary care hospital. *Int J Curr Res Rev*. 2013;5:80-86.

31. Ibukun A,Tolu O,Brian JM.Extended-spectrum β -lactamases in isolates of *Klebsiella spp* and *Escherichia coli* from Lagos,Nigeria.*Nig J Health Biomed Sci*.2003;2:53-60.<https://doi.org/10.4314/njhbs.v2i2.11484>
32. Shafiq M,Rahman H,Qasim M,Ayub N,Hussain S,Khan J,et al.Prevalence of plasmid-mediated ampC β -lactamases in *Escherichia coli* and *Klebsiella pneumoniae* at tertiary care hospital of Islamabad,Pakistan.*Euro J Microbiol Immunol*.2013;4:267-271.<https://dx.doi.org/10.1556%2FEuJMI.3.2013.4.5>
33. Owens RC Jr,Irice L.Hospital based strategies for combating resistance.*Clinical Infectious Disease*.2006;42:S173-81.(Accessed 15th April,2006 Available from: <https://doi.org/10.1086/500664>
34. Khanal S,Joshi DR,Bhatta DR,Devkota U,Pokhrel BM.Beta-lactamase-producing multidrug-resistant bacterial pathogens from tracheal aspirates of intensive care unit patients at National Institute of Neurological and Allied Sciences,Nepal.*ISRN Microbiology*.2013;5.<https://doi.org/10.1155/2013/847569>
35. Al-Zarouni M,Senok A,Rashid F,Al-Jesmi SM,Panigrahi D.Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase producing Enterobacteriaceae in the United Arab Emirates.*Med Princ and Prac*.2008;17(1):32-36.<https://doi.org/10.1159/000109587>
36. Dalela G,Gupta S,Jain DK, Mehta P.Antibiotic Resistance Pattern in Uropathogens at a Tertiary Care Hospital at Jhalawar with Special Reference to ESBL,AmpC β -Lactamase and MRSA Production. *J Clin D R*. 2012; 6 (4):645-651.
37. Ozcakar ZB,Yalcinkaya F,Kavaz A,Kadioglu G,Elhan AH,Aysev D,Guriz H,Ekim M.Urinary tract infections owing to ESBL-producing bacteria:microorganisms change-clinical pattern does not.*Acta Paediatr*.2011; 100(8):61-4.<https://doi.org/10.1111/j.1651-2227.2011.02262.x>
38. Nass T,Poirel L and Nordmann P.Minor extended spectrum β -lactamases.*Clin Microbiol Infect*.2008;14:42-52.<https://doi.org/10.1111/j.1469-0691.2007.01861.x>
39. Marthie ME,Chrisna V,Eddy PM,Michael GD,Anwar AH,Marleen MK.Detection of bla SHV,blaTEM and blaCTX-M antibiotic resistance genes in randomly selected bacterial pathogens from the Steve Biko Academic Hospital.*Immunol Med Microbiol*.2009;56:191-196. <https://doi.org/10.1111/j.1574-695x.2009.00564.x>
40. Majid K,Majid B,Fateh R.Detection of TEM,SHV and CTX-M Antibiotic Resistance Genes in *Escherichia coli* Isolates from Infected wounds.*Medical Laboratory Journal*.2017;11(2):30-35.<http://dx.doi.org/10.18869/acadpub.mlj.11.2.30>
41. Ruben F,Paula A,Carla O,Cristina P.Molecular Characterization of ESBL-Producing Enterobacteriaceae in Northern Portugal.*The Scientific World Journal*.2014;6.<https://doi.org/10.1155/2014/782897>

42. Noha AH,Ahmed SK,Eman MF,Adel MH,Medhat AF.Molecular characterization of Extended-spectrum β lactamase-producing *E.coli* recovered from community-acquired urinary tract infections in Upper Egypt.2020; 10:2772 <https://doi.org/10.1038/s41598-020-59772-z>
43. Pandit R,Awal B,Shrestha SS,Joshi G,Rijal BP,Parajuli NP.Extended-Spectrum β -lactamase(ESBL) Genotypes among Multidrug-Resistant Uropathogenic *Escherichia coli* Clinical Isolates from a Teaching Hospital of Nepal.Interdisciplinary Perspectives on Infectious Diseases.2020;8.<http://doi.org/10.1155/2020/6525826>
44. Bali EB,Acik L,Sultan N.Phenotypic and molecular characterization of SHV,TEM,CTX-M and extended-spectrum β -lactamase produced by *Escherichia coli*,*Acinetobacter baumannii* and *Klebsiella* isolates in a Turkish hospital.*African Journal of Microbiology Research*.2010;4(8):650-654.<https://doi.org/10.5897/AJMR.9000551>
45. Michael NS,Saadi AT.Detection of bla CTX-M,blaTEM01 and blaSHV Genes in Multidrug Resistant Uropathogenic *E.coli* Isolated from Patients with Recurrent Urinary Tract Infections.*International Journal of Medical Research & Health Sciences*.2018;7(9):81-89.
46. Jena J,Sahoo RK,Debata NK,Subudhi E.Prevalence of TEM,SHV,and CTX-M genes of extended-spectrum beta-lactamases-producing *Escherichia coli* strains isolated from urinary tract infections in adults.*Biotech*.2017;7(4):244.<https://doi.org/10.1007/s13205-017-0879-2>
47. Seyedjavadi SS,Goudarzi M and Sabzehali F.Relation between blaTEM,blaSHV and blaCTX-M genes and acute urinary tract infections.*J Acute Dis*.2016;5:71-76.<https://doi.org/10.1016/j.joad.2015.07.007>
48. Pokhrel RH,Thapa B,Kafle R,Shah PK and Tribuddharat C.Co-existence of β -lactamases in clinical isolates of *Escherichia coli* from Kathmandu,Nepal.*BMC Res Notes*.2014;7:694.<https://doi.org/10.1186/1756-0500-7-694>
49. Lohani B,Thapa M,Sharma L,Adhikari H,Sah AK,Khanal AB,Basnet RB and Aryal M.Predominance of CTX-M Type Extended Spectrum β -lactamase(ESBL) Producers Among Clinical Isolates of Enterobacteriaceae in a Tertiary Care Hospital,Kathmandu,Nepal. *The OpenMicrobiology Journal*.2019;13:28-33.<http://dx.doi.org/10.2174/1874285801913010028>
50. Bonnet R. Growing Group of Extended-Spectrum β -Lactamases:the CTX-M Enzymes.*Antimicrob Agents Chemother*.2004;48(1)1-14.<https://doi.org/10.1128/aac.48.1.1-14.2004>
51. Livermore DM,Canton R,Gniadkowski M,Nordmann P,Rossolini GM,Arlet G,Ayala J,Coque TM,Kern-Zdanowicz I,Luzzaro F,Poirel L,Woodford N.CTX-M:changing the face of ESBLs in Europe.*J Antimicrob Chemother*.2007; 59:165-174.<https://doi.org/10.1093/jac/dkl483>
52. Canton R and Coque TM. The CTX-M β -lactamase pandemic.*Curr Opin Microbiol*.2006; 9:466-475.<https://doi.org/10.1016/j.mib.2006.08.011>

53. Canton R, Gonzalez-Alba JM and Galan JC. CTX-M enzymes: origin and diffusion. *Front. Microbiol.* 2012;3:110. <https://doi.org/10.3389/fmicb.2012.00110>
54. Parajuli NP, Maharjan P, Joshi G and Khanal PR. Emerging Perils of Extended Spectrum β -Lactamase Producing Enterobacteriaceae Clinical Isolates in a Teaching Hospital of Nepal. *Biomed Research International*. 2016; 7. <http://dx.doi.org/10.1155/2016/1782835>
55. George EA, Sankar S, Jesudasan MV, Sudandiradoss C and Nandagopal B. Molecular characterization of CTX-M type extended spectrum β -lactamase producing *E. coli* isolated from humans and the environment. *Indian J Med Microbiol.* 2015;33:73-79. <http://dx.doi.org/10.4103/0255-0857.150896>
56. Moses A, Bwanga F, Boum Y, and Bazira J. "Prevalence and genotypic characterization of extended-spectrum beta-lactamases produced by gram negative bacilli at a tertiary care hospital in Rural South Western Uganda". *British Microbiology Research Journal*. 2014;4(12):1541-1550. <https://doi.org/10.9734/bmrj/2014/9792>
57. Sharma M, Pathak S and Srivastava P. "Prevalence and antibiogram of Extended Spectrum β -lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing *Escherichia coli* and *Klebsiella* spp" *Journal of Clinical and Diagnostic Research*. 2013;7(10):2173-2177. <https://doi.org/10.7860/jcdr/2013/6460.3462>
58. Kiratisin P, Apisarnthanarak A, Laesripa C, and Saifon P. "Molecular characterization and epidemiology of extended-spectrum- β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates causing Health care-associated infection in Thailand, where the CTX-M family is endemic". *Antimicrobial Agents and Chemotherapy*. 2008;52(8):2818-2824. <https://doi.org/10.1128/aac.00171-08>
59. Al-Agamy, Mohammad HM, Atef M, Shibl, and Abdelkader F, Tawfik. "Prevalence and molecular characterization of extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* in Riyadh, Saudi Arabia." *Annals of Saudi Medicine*. 2009; 29 (4):253. <https://doi.org/10.4103/0256-4947.55306>
60. Polse RF, Yousif SY, and Assafi MS. Prevalence and molecular characterization of extended spectrum β -lactamases producing uropathogenic *Escherichia coli* isolated in Zakho, Iraq. *J Microbiol Infect Dis*. 2016; 6(4):163-167. <https://doi.org/10.5799/jmid.328863>
61. Kaftandzieva A, Trajkovska-Dokic E, and Panovski N. Prevalence and molecular characterization of extended spectrum β -lactamases (ESBLs) producing *Escherichia coli* and *Klebsiella pneumoniae*. *Prilozi*. 2011;32:129-141.
62. Ibrahim AL-Subol, Youssef N. Prevalence of CTX-M, TEM and SHV Beta-lactamase in Clinical Isolates of *Escherichia coli* and *Klebsiella pneumoniae* Isolated from Aleppo University Hospitals, Aleppo, Syria. *Arch Clin Infect Dis*. 2015;10(2):e22540. <https://dx.doi.org/10.5812/archcid.22540>

63. El bouamri MC,Arsalane L,Zerouali K,Katfy K,El kamouni Y,Zouhair S.Molecular characterization of extended spectrum β -lactamase-producing *Escherichia coli* in a university hospital in Morocco,North Africa.*African Journal of Urology*.2015;21:161-166.<https://doi.org/10.1016/j.afju.2015.02.005>
64. Du J,Li P,Liu H,Lu D,Liang H and Dou Y.Phenotypic and molecular characterization of multidrug resistant *Klebsiella pneumoniae* isolated from a university teaching hospital,China.*Plos one*.2014; 9(4):e95181.<http://doi.org/10.1371/journal.pone.0095181>
65. Varkey DR,Balaji V,and Abraham J.Molecular characterization of extended spectrum β -lactamase producing strains from blood sample.*Int J Pharm Sci*.2014;6:276-278.

Figure

Figure is not available with this version.